A hidden weakness in deadly cancers could lead to powerful new treatments

Researchers at UCLA uncovered a significant weakness in small cell cancers that have historically evaded effective treatments. They discovered that tumors missing the RB gene rely heavily on the protein E2F3 to survive. By blocking E2F3, tumor growth was halted in lab models, and existing FDA-approved drugs might target this vulnerability. This breakthrough could expedite the development of more potent therapies, offering hope for patients with a notoriously aggressive form of cancer.